30 results about "Hippocampal neuron" patented technology

The invention discloses construction and application of a Primrose syndrome non-human animal model, and belongs to the technical field of animal models and disease research. According to the invention, through a CRISPR / Cas9 technology, a codon CAC for coding 596th histidine in a No.14 exon of a mouse Zbtb20 gene is subjected to site-directed mutagenesis into CGC for coding arginine, and a hybrid mouse model for simulating pathogenic point mutation (p.H596R) of human Primrose syndrome is constructed. The model can stably reproduce key clinical phenotypes of the Primrose syndrome, including overgrowth after adult, serum IGF-1 rise, memory dysfunction and anxiety behaviors, and shows abnormal hippocampal neuronal development and synaptic transfer related pathways and the like. The invention provides an important experimental tool for deeply revealing the pathological mechanism of Primrose syndrome, developing drug screening and treatment intervention research and the like.

The invention discloses a compound with remarkable 5-hydroxytryptamine (5-HT) reuptake inhibition activity, a preparation method of the compound and application of the compound in preparation of anti-depression drugs. And the compound is a compound Oreonudine C. The invention further discloses a preparation method of the compound. The preparation method of the Oreonudine C comprises the following steps: extracting with 95% ethanol, acidifying the extract, extracting with petroleum ether, adjusting the acid water layer to be alkaline with alkali liquor, extracting with chloroform, and performing silica gel column chromatography, C18 ODS column chromatography and preparative high performance liquid chromatography on the chloroform extraction part to obtain the Oreonudine C. The invention further discloses a preparation method of the Oreonudine C. The preparation method of the Oreonudine C comprises the following steps: extracting with 95% ethanol, acidifying the extract, extracting with petroleum ether, adjusting the acid water layer to be alkaline with alkali liquor, and obtaining the Oreonudine C. In-vitro experiments show that the compound Oreonudine C remarkably inhibits reabsorption of 5-HT (the inhibition rate is 60.4%) in mouse hippocampal neuronal cells HT22, and the inhibition rate of the compound Oreonudine C is superior to that of a positive control drug amitriptyline (the inhibition rate is 53.6%). The invention provides an important candidate compound for developing efficient and novel antidepressant drugs.

The application discloses expression regulation of alpha-synuclein and application thereof. The alpha-synuclein inhibitor is used for preparing a medicine, and the obtained medicine has the effects of preventing and treating anxiety caused by social isolation. Experiments prove that after the alpha-synuclein inhibitor is administered, the anxiety behavior of a model animal in a social isolation environment can be improved, and the alpha-synuclein inhibitor has a treatment effect on anxiety caused by social isolation. The alpha-synuclein inhibitor is selected from the following: 1) an ASO targeting SNCA mRNA coding alpha-synuclein; 2) a small-molecule compound targeting SNCA mRNA coding alpha-synuclein; or 3) an AAV interfering with the expression level of alpha-synuclein in a ventral hippocampal neuron.

The invention discloses application of a miR-5588-3p inhibitor, and belongs to the technical field of biological medicines. Researches find that the expression of miR-5588-3p in the plasma of an epileptic is abnormally increased. The miR-5588-3p inhibitor is given 72 hours before the tree shrew epilepsy model is constructed, so that the attack level, the convulsion rate and the death rate of the epilepsy tree shrew can be effectively reduced, and the brain pathological injury of the epilepsy tree shrew can be relieved. The miR-5588-3p inhibitor disclosed by the invention is used for preparing a medicine for treating epilepsy, and the nucleotide sequence of the miR-5588-3p inhibitor is as follows: GCUGGCAUUAGUGGGACUU. According to the present invention, the convulsion rate and the death rate of the epilepsy tree shrew can be well reduced, the matrix incubation period and the convulsion incubation period of the epilepsy tree shrew can be effectively prolonged, the convulsion duration of the epilepsy tree shrew can be shortened, the attack level of the epilepsy tree shrew can be effectively reduced, and the miR-5588-3p inhibitor can significantly reduce the hippocampal neuron damage.

The application discloses an IGFBP-2 derived polypeptide and application thereof in preparation of an antidepressant, and relates to the technical field of biological medicines. The amino acid sequence of the polypeptide is Pro-Lys-Lys-Leu-Arg-Pro, the N terminal of which is acetylated and the C terminal of which is amidated, and the amino acid sequence is shown as SEQ ID NO:1. The polypeptide has a small molecular weight, can easily penetrate the blood-brain barrier, and has good stability after terminal modification. Animal experiments prove that the polypeptide can significantly improve the depressive behavior of Shank3 gene knockout mice, including improving the spatial cognitive ability, enhancing the social interaction and curiosity, and relieving the anxiety behavior. Cell experiments prove that the polypeptide can significantly improve the viability of hippocampal neuron cells from Shank3 gene knockout mice, and up-regulate the expression level of synaptic plasticity related proteins GluA1 and SYN1. The polypeptide can be prepared by a chemical synthesis method, has low cost, and can be used for preparing a medicine for preventing or treating depression (especially depression related to Shank3 gene mutation).

The application belongs to the technical field of medicine, and particularly relates to a muscone derivative, a preparation method and application thereof. The muscone derivative cyclopentadecanedione monoxime has obvious advantages over muscone and other derivatives in improving the MCAO rat mNSS score, microcirculation blood flow, reducing the cerebral infarction rate, the cortical and hippocampal neuron necrosis rate, and the brain water content, and increasing the SOD and CAT contents of the rat brain tissue which are abnormally reduced due to ischemia, and is a potential effective drug for cerebral ischemia-reperfusion injury.

The application relates to the technical field of medicines, in particular to application of glycyrrhiza chalcone A in preparation of medicines for treating depression. The application experiment shows that the glycyrrhiza chalcone A can significantly improve the CUMS-induced depression-like behavior of mice, reduce the hippocampal neuron damage, inhibit the neuroinflammatory reaction, and restore the 5-HT level, and the anti-depression mechanism may be closely related to multiple mechanisms such as down-regulation of MAPK / JNK path activity, inhibition of inflammatory factor expression and neurotransmitter regulation.

The application relates to the technical field of medicines, and particularly discloses a polypeptide and application of the polypeptide in preparation of a medicine for ischemic stroke. The amino acid sequence of the polypeptide is as shown in SEQ ID NO. 1. The polypeptide can significantly improve the nerve function defect of a mouse transient middle cerebral artery occlusion / reperfusion (tMCAO / R) model in vivo, reduce the cerebral infarction volume, and reduce the whole-body oxidative stress level. In vitro, the polypeptide has a direct protective effect on HT22 cells of mouse hippocampal neurons and hCMEC / D3 cells of human brain microvascular endothelium induced by oxygen-glucose deprivation (OGD), can resist the damage of corticosterone and MPP + induced PC12 cells, and effectively inhibits the accumulation of reactive oxygen species (ROS) in cells. The results show that the polypeptide has a multi-target cell protection activity, can play an anti-ischemic stroke role from multiple dimensions such as reduction of infarction volume, inhibition of oxidative stress level, and protection of nerve vascular units.

The invention provides a traditional Chinese medicine composition for treating Parkinson's depression and a preparation method and application thereof, and belongs to the technical field of traditional Chinese medicines. The traditional Chinese medicine composition is prepared from the following raw materials in parts by weight: 1-10 parts of radix acanthopanacis semticosi and 1-10 parts of bulbus lilii. The invention also provides a preparation method of the traditional Chinese medicine composition, which comprises the following steps: taking the acanthopanax and the lily, adding water to soak, heating, refluxing and extracting, and combining filtrate to obtain the traditional Chinese medicine composition. Animal experiments find that the acanthopanax-lily traditional Chinese medicine composition has a good treatment effect on Parkinson depression for the first time, and can remarkably improve dyskinesia and depression symptoms, regulate neurotransmitter disorder, relieve damage to nigra and hippocampal neurons and reduce the level of inflammatory factors in serum. After being taken for a long time, the traditional Chinese medicine composition disclosed by the invention can improve depression and life quality, slow down the progress of Parkinson disease and reduce the use of Parkinson drugs.

The invention relates to the technical field of bioactive peptides, in particular to application of sipunculus nudus polypeptide in preparation of a neuroprotective drug. According to the specific technical scheme, firstly, sipunculus nudus oligopeptide is obtained through enzymolysis and an ultrafiltration membrane separation technology, the sipunculus nudus oligopeptide is separated and purified through sephadex chromatography, and on the basis of a high-glucose-induced mouse hippocampal neuron HT22 cell damage model, the collected components are separated and purified to obtain the sipunculus nudus oligopeptide. The neuroprotective effects of the sipunculus nudus oligopeptide and the separated components thereof are deeply discussed, and then the components in the sipunculus nudus oligopeptide are further separated and purified and subjected to mass spectrum peptide sequence identification by adopting reverse-phase high performance liquid chromatography. Experimental results show that the three components separated from the sipunculus nudus oligopeptide through sephadex chromatography can effectively improve the cell activity of HT22 cells after high glucose damage, and accumulation of ROS (reactive oxygen species) in the cells and occurrence of apoptosis are remarkably reduced.

The invention relates to the technical field of medicines, in particular to an iridium-kaempferol complex as well as a preparation method and application thereof. One Ir (Cp *) Cl2 structure in [Ir (Cp *) Cl2] 2 is substituted by one C15H10O6 to prepare the iridium-kaempferol complex, an Ir (III) center is combined with a kaempferol ligand for the first time, the metal organic complex Ir-Kae which not only utilizes the stability of the Ir (III) complex but also utilizes the pharmacological activity of kaempferol is developed, and through the synergistic effect of multiple mechanisms such as oxidation resistance, inflammation resistance and neuroprotection, the metal organic complex Ir-Kae can be used for preparing the metal organic complex. The spinal cord injury can be effectively treated at multiple target points. The Ir-Kae has a remarkable free radical scavenging capability, can effectively reduce the level of active oxygen in cells and organisms, realizes remarkable oxidation resistance and oxidative stress resistance, can improve the living and death degree of damaged hippocampal neurons, promotes neuronal repair, and has a remarkable anti-aging effect on hippocampal neurons. The nerve injury and the spinal cord injury are effectively treated, and a new direction is provided for assistant treatment of the spinal cord injury medicine.

The invention discloses a medicinal and edible composition for delaying cognitive and memory function decline of old people, which comprises a fructus piperis longi extract, a radix asparagi extract and sodium hyaluronate, and is combined with highland barley, common turnip, maca, D-psicose and other active substances to prepare the medicinal and edible composition for delaying cognitive and memory function decline of old people. A series of medicinal and edible compositions for improving cognitive and memory function decline of old people are developed. The composition disclosed by the invention has a good protective effect in delaying senile cognitive and memory function decline, can be applied to senile cognitive and memory function decline accompanied by age increase, enhances the activity of telomerase, and improves neurotransmitter homeostasis and brain health. Molecular mechanism research shows that the compound can reverse senescence of neuronal cells of hippocampus by activating key targets in a phosphatidylinositol-3-kinase / protein kinase B signal channel. The composition can be used for being developed into food and health care products for improving attention, learning ability, language ability and judgment, has safety and effectiveness, and has a very good application prospect.

The application discloses an antiepileptic preparation preparation method and application of a micro ribonucleic acid 145b targeting agent, and relates to the technical field of biological medicine. The method comprises the following steps: constructing a neuron-specific recombinant adeno-associated virus plasmid vector, wherein the vector comprises a neuron-specific promoter hSyn, a reporter gene, an enhancer, and a functional nucleic acid sequence for targeting and inhibiting micro ribonucleic acid 145b; using an adeno-associated virus packaging system to transfect the vector to a packaging cell for virus packaging; collecting a lysis solution and separating out a recombinant adeno-associated virus particle through a purification process; and resuspending the virus particle to obtain a preparation. The application specifically down-regulates the miR-145b level in hippocampal neurons, releases the inhibition of the Kcnq3 potassium ion channel, further up-regulates the Kcnq3 expression, restores the M current, and reduces the neuron excitability from a molecular mechanism.

The application belongs to the field of medicine and relates to application of an isoflavone compound, isoformononetin (IFM), in preparation of a medicine or health care product for preventing and treating depression; in mouse hippocampal neuron cells (HT22) or mouse microglial cells (BV2), IFM can reduce neuroinflammation caused by corticosterone (CORT) or lipopolysaccharide (LPS) and increase the expression level of brain-derived neurotrophic factor (BDNF); in a chronic mild unpredictable stress mouse depression model, IFM can relieve depression-like behavior of the mouse and reduce the inflammation level of brain tissue, indicating that IFM has a good effect of relieving depression; IFM degrades PDE4D protein by directly combining with a PDE4D target protein. The isoflavone compound IFM has the advantages of outstanding effect and high safety and is expected to develop into an effective medicine for treating and preventing depression.

The application belongs to the field of traditional Chinese medicines, and discloses a traditional Chinese medicine supramolecular nanoparticle, which is prepared from Uncaria as a raw medicinal material, is extracted by heating reflux with 68-72% ethanol, is filtered, and is dried after being dialyzed after being dispersed in pure water, centrifuged, resuspended, and centrifuged again. The traditional Chinese medicine supramolecular nanoparticle has uniform particle size, a narrow particle size distribution, and high stability. The nanoparticle has obvious anti-nerve oxidation and obvious nerve protection effects according to in-vitro cell activity detection. The nanoparticle has good in-vivo nerve protection effect, can improve memory impairment and cognitive impairment, and can prevent hippocampal neuron reduction. Compared with Uncaria effective parts, the effective administration dose of the traditional Chinese medicine supramolecular nanoparticle is obviously reduced. The application also discloses a use of the traditional Chinese medicine supramolecular nanoparticle in preparation of a medicine for treating nervous system diseases.

The invention discloses an application of Naozhenning granules in preparation of drugs for inhibiting cGAS-STING pathways, and belongs to the technical field of modernization of traditional Chinese medicine, systematic in-vitro experiments prove that Naozhenning drug-containing serum can significantly inhibit excessive activation of cGAS-STING signal pathways in LPS-induced BV2 microglial cells and HT22 hippocampal neuronal cells, and can inhibit the cGAS-STING signal pathways in LPS-induced BV2 microglial cells and HT22 hippocampal neuronal cells. Specifically, the expression of proteins and mRNA of cGAS, STING and IRF3 is down-regulated, and the release of mtDNA is reduced, so that the polarization of microglial cells M1 is inhibited, the levels of proinflammatory factors such as IL-18, TNF-alpha and IFN-gamma are reduced, and the survival and proliferation of cells are promoted; particularly, it is found that the Naozhenning granules and the STING inhibitor SN-011 have a synergistic effect, and a brand new scientific basis and an application direction are provided for the Naozhenning granules in preparation of drugs for treating cGAS-STING pathway related nervous system diseases such as post-concussion syndromes.

This invention discloses the application of a natural isoflavone compound in the preparation of drugs for the prevention or treatment of depression. The natural isoflavone compound is hematoxylin A, a derivative of hematoxylin A, or a pharmaceutically acceptable salt of hematoxylin A. Hematoxylin A can effectively reduce oxidative damage to HT22 neurons in the hippocampus induced by glutamate and corticosterone, and can significantly improve the behavioral performance of mice in a chronic restraint stress depression model, exhibiting clear antidepressant activity. Hematoxylin A has a well-defined structure and good safety profile, showing promising application prospects in the development of antidepressant drugs.

A small molecule polypeptide interfering with the combination of CD44 and STAT3, a pharmaceutical composition thereof and application, the amino acid sequence of the polypeptide is shown as SEQ ID NO: 1 (TGNYKALHPHNG-DQFMTADE). The polypeptide is based on the polypeptide fragment homologous to the intracellular segment of CD44, and the brain-targeting cell-penetrating peptide (TGNYKALHPHNG) is connected to the N-terminal of the polypeptide fragment, and the polypeptide fragment homologous to the intracellular segment of CD44 is the sequence DQFMTADE at positions 722-729 and can specifically bind to STAT3. The polypeptide specifically interferes with the combination of CD44 and STAT3, inhibits the phosphorylation of STAT3, down-regulates the apoptosis-related signal pathway, reduces the apoptosis of hippocampal neurons, thereby improves diabetic cognitive impairment, and has the advantages of high specificity, low toxicity, good penetration and the like, and provides a new strategy for the treatment of diabetic cognitive impairment.

This invention provides an application of Pulsatilla Decoction in the preparation of drugs for treating cognitive impairment. It significantly improves spatial learning and memory, recognition memory, and anxiety-depression-like behaviors in model mice, while increasing cerebral blood flow, reducing hippocampal neuronal damage, and effectively regulating the levels of neurotransmitters such as tryptophan, 5-HT, dopamine, and GABA in the brain. This formula exerts a central protective effect while alleviating intestinal inflammation, demonstrating the dual regulatory advantage of the gut-brain axis. Furthermore, its active ingredient, Pulsatilla saponin B4, also has the effect of improving cognitive function. This invention provides a scientific basis for the "repurposing" of classic formulas, possessing clear efficacy, good safety, and mature preparation technology, and has good prospects for clinical translation.

This invention discloses a 3-hydroxypyridinone derivative, its preparation method, and its applications. This 3-hydroxypyridinone derivative, through structural modification of the 3-hydroxypyridinone core, significantly enhances its anti-ferroptosis activity against hippocampal neurons in HT-22 mice. In vitro experiments show that its inhibitory effect on ferroptosis is more than twice that of the positive control deferoxone. Furthermore, the 3-hydroxypyridinone derivative can also chelate Fe... 3+ To alleviate iron-mediated Aβ 1‑42 Protein aggregation and its cytotoxicity. This invention also provides synthetic routes, purification methods, and in vitro activity evaluation systems for 3-hydroxypyridinone derivatives, offering structural optimization strategies and candidate compounds for the development of drugs targeting iron metabolism disorders.

The invention relates to the technical field of marine organisms, in particular to aptamer-modified nerve cell membrane hybrid lipidosome, a preparation method thereof and application of the aptamer-modified nerve cell membrane hybrid lipidosome in domoic acid detoxification. According to the invention, a cell membrane of a human hippocampal neuron HPPNCs cell line is hybridized with liposome, and then the surface of the cell membrane is modified with an aptamer which is specifically combined with domoic acid. High performance liquid chromatography detection and cellular level experiments both prove that after incubation treatment of the aptamer-modified nerve cell membrane hybrid liposome, the concentration of domoic acid in a system is obviously reduced, apoptosis and oxidative stress damage caused by domoic acid to nerve cells can be obviously improved, and the aptamer-modified nerve cell membrane hybrid liposome has detoxification capacity on domoic acid. The invention develops a new detoxification idea for the field of prevention and treatment of domoic acidosis, and has application potential.

This invention discloses the application of Polygonatum odoratum carbon quantum dots (PC-CQDs) in the preparation of drugs for treating vascular dementia, belonging to the field of pharmaceutical technology. This invention is the first to apply PC-CQDs to the treatment of vascular dementia. Morris water maze test and hippocampal histopathological analysis confirmed that PC-CQDs can significantly improve spatial learning and memory abilities in VaD rats, protect hippocampal neurons, and exhibit good biocompatibility. This invention provides a new drug option for the treatment of vascular dementia, possessing significant clinical application value and broad market prospects.

This invention discloses the application of GGCX in the preparation of reagents for the diagnosis or auxiliary diagnosis of ischemic stroke. First, a six-layer progressive genetic evidence system was constructed to confirm that upregulation of gamma-glutamyl carboxylase (GGCX) is a protective factor against ischemic stroke, and that the protective effect is subtype-specific. Second, a diagnostic model was constructed based on peripheral blood GGCX expression data. Finally, the significant downregulation of GGCX under ischemic conditions was verified through three levels: clinical sample qPCR detection, tMCAO / R animal model, and primary hippocampal neuronal OGD / R cell model, with an AUC value of 0.889 in the clinical validation cohort. This invention provides a reliable approach for the early auxiliary diagnosis of ischemic stroke based on the peripheral blood biomarker GGCX. It has clear clinical value and significance for improving the early diagnosis rate of ischemic stroke and shortening the time from onset to treatment.

The invention relates to a polypeptide, a derivative of the polypeptide, a conjugate of the polypeptide and new application of the polypeptide. The amino acid sequence of the polypeptide is as shown in SEQ ID No. 1. The polypeptide can reverse the weakening of cell proliferation activity of mouse hippocampal neuron cells HT-22 induced by an A beta1-40 oligomer, and reduce p-Tau protein overexpression and cell axon structure damage in the HT-22 cells caused by the A beta1-40 oligomer; the polypeptide promotes the proliferation and differentiation of the neural stem cell line C17.2 cells treated by the A beta1-40 oligomer; the polypeptide can significantly improve Alzheimer's disease related pathological changes in cerebral cortex and hippocampus of a mouse and promote neurogenesis of the hippocampus, so that related cognitive functions of learning, memory and the like of an Alzheimer's disease model mouse are recovered, and the effect of treating the Alzheimer's disease is achieved; the polypeptide can be used for preparing a low-toxicity, safe and effective Alzheimer's disease therapeutic agent, and a new way is provided for treating Alzheimer's disease.

The invention relates to the technical field of biological active substance extraction and health food, in particular to green brick tea theabrownin, a preparation method of the green brick tea theabrownin and application of the green brick tea theabrownin to preparation of products for improving circadian rhythm disorder and depression-like behaviors. The green brick tea theabrownin is obtained. The extracted green brick tea theabrownin has an improvement effect on the depressive mood behavior of a mouse with circadian rhythm disorder; the metabolism and immune injury of mice with circadian rhythm disorder can be relieved by improving lipid metabolism and inhibiting inflammatory response; multi-organ pathological injury of the mice with circadian rhythm disorder can be protected, so that edema of colonic mucosa of the mice is reduced, fatty degeneration of liver is relieved, and hippocampal neuron injury is relieved; and the rhythm disorder of the central clock gene of the circadian rhythm disorder mouse can be repaired by adjusting the expression of the central clock gene.

The invention discloses application of schizonepeta polysaccharide in preparation of drugs or health care products for treating or preventing Alzheimer's disease. Various animal models verify that the schizonepeta polysaccharide has multiple biological functions of remarkably prolonging the life of nematodes with Alzheimer's disease, improving the cognitive function of transgenic mice, protecting hippocampal neurons, inhibiting neuroinflammation, clearing A beta plaques, regulating the diversity of intestinal flora and the like. The schizonepeta polysaccharide as a polysaccharide component of a natural plant source has the advantages of definite drug effect, high safety, various action mechanisms and the like, provides a new drug choice for prevention and treatment of the Alzheimer's disease, and has wide clinical application prospect and development value.

The application belongs to the technical field of biological medicine, and discloses a nano regulator for treating cerebral hemorrhage, a preparation method and application thereof. First, a DNA nanoflower containing a hybridization site is prepared based on RCA technology, and is hybridized with a T structure containing a target transferrin receptor, so that the obtained carrier has the ability to cross the blood-brain barrier and gather at the damage site. Then, the nano regulator TNF@Gin is obtained by loading ginkgo flavones through non-covalent interaction. The obtained nano regulator can promote the polarization of microglial cells to the anti-inflammatory M2 phenotype, thereby reducing the level of pro-inflammatory factors and relieving excessive inflammatory response. In addition, the nano regulator can effectively clear ROS and Nrf2 / GPX4 signal pathway, and inhibit the ferroptosis of hippocampal neuron cells. The nano regulator shows high and safe treatment results, and provides a new strategy for treating cerebral hemorrhage.

This invention provides lactylated PRDX5 protein, its products, and applications, belonging to the field of biomedical technology. This invention reveals the crucial role of PRDX5 K71 site lactylation modification in the pathological process of COPD, showing abnormally elevated levels of lactylation in hippocampal neurons of COPD mice, which is closely related to the occurrence and development of cognitive impairment in mice. Simultaneously, it provides a specific intervention protocol targeting this site. Stereoscopic injection of recombinant adeno-associated virus PRDX5 K71R mutant reduces or blocks the likelihood of lactylation modification at the K71 site, effectively improving learning, memory, and spatial orientation abilities in COPD mice. This provides new molecular targets and experimental evidence for the study of the mechanisms of cognitive impairment and targeted prevention and treatment.

This invention provides the application of Tongren Niuhuang Qingxin Pill in the preparation of drugs for the prevention and treatment of acute mountain sickness, relating to the field of pharmaceutical formulation technology. In the application of Tongren Niuhuang Qingxin Pill in the preparation of drugs for the prevention and treatment of acute mountain sickness, it improves mitochondrial structure and function by regulating the expression of nuclear respiratory factor Nrf1 protein, protecting hippocampal neurons, and enhancing the learning and memory abilities of model rats. It can also improve brain tissue water homeostasis in rats with acute mountain sickness through anti-oxidative stress, thereby achieving a preventive and therapeutic effect on acute mountain sickness in rats.

The invention discloses a compound with remarkable noradrenaline (NE) reuptake inhibition activity and application of the compound in preparation of an anti-depression drug. The compound is a compound Oreonudine F. The preparation method of the compound comprises the following steps: extracting an overground part of wild poppy by using 95% ethanol, acidifying an extract, extracting by using petroleum ether, adjusting an acid water layer to be alkaline by using alkali liquor, and extracting by using chloroform. The chloroform extraction part is subjected to silica gel column chromatography, C18 ODS column chromatography, preparative high performance liquid chromatography separation and the like, and the compound Oreonudine F is obtained. In-vitro activity test results show that the compound Oreonudine F significantly inhibits reabsorption of NE (the inhibition rate is 45.6%) in mouse hippocampal neuronal cells HT22, and the inhibition rate of the compound Oreonudine F is superior to that of a positive control drug amitriptyline (the inhibition rate is 35.5%). The invention provides an important candidate compound for developing efficient and novel antidepressant drugs.